1009075-43-7 Usage
Uses
Used in Pharmaceutical Industry:
(3S,4S)-tert-Butyl 3-amino-4-fluoropyrrolidine-1-carboxylate is used as a key intermediate in the synthesis of various pharmaceutical and biologically active compounds. Its unique structure and chirality make it a valuable component in the development of novel drugs.
Used in Synthesis of Aminopyrrolidine Derivatives:
(3S,4S)-tert-Butyl 3-amino-4-fluoropyrrolidine-1-carboxylate is used as a starting material for the preparation of novel aminopyrrolidine derivatives. These derivatives have potential applications in various therapeutic areas, including central nervous system disorders, cardiovascular diseases, and oncology.
Used in Factor Xa Inhibitors:
(3S,4S)-tert-Butyl 3-amino-4-fluoropyrrolidine-1-carboxylate is used as a crucial component in the development of factor Xa inhibitors, which are a class of anticoagulant drugs. These inhibitors selectively target the factor Xa enzyme, an essential component in the blood coagulation process, thereby reducing the risk of thrombotic events.
Check Digit Verification of cas no
The CAS Registry Mumber 1009075-43-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,9,0,7 and 5 respectively; the second part has 2 digits, 4 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1009075-43:
(9*1)+(8*0)+(7*0)+(6*9)+(5*0)+(4*7)+(3*5)+(2*4)+(1*3)=117
117 % 10 = 7
So 1009075-43-7 is a valid CAS Registry Number.
1009075-43-7Relevant academic research and scientific papers
SELECTIVELY SUBSTITUTED QUINOLINE COMPOUNDS
-
Paragraph 0447; 0455, (2015/04/21)
Embodiments of the disclosure relate to selectively substituted quinoline compounds that act as antagonists or inhibitors for Toll-like receptors 7 and/or 8, and their use in pharmaceutical compositions effective for treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit
Zbinden, Katrin Groebke,Anselm, Lilli,Banner, David W.,Benz, Joerg,Blasco, Francesca,Decoret, Guillaume,Himber, Jacques,Kuhn, Bernd,Panday, Narendra,Ricklin, Fabienne,Risch, Philippe,Schlatter, Daniel,Stahl, Martin,Thomi, Stefan,Unger, Robert,Haap, Wolfgang
body text, p. 2787 - 2795 (2009/10/17)
Starting from a hit identified by focused screening, 3-aminopyrrolidine factor Xa inhibitors were designed. The binding mode as determined by X-ray structural analysis as well as the pharmacokinetic behaviour of selected compounds is discussed.
